Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Neuroblastoma 18Gliosarcoma 7Glioblastoma 7Brain Neoplasms 7Glioma 5Central Nervous System Neoplasms 5Astrocytoma 5Sarcoma 3Oligodendroglioma 3Neoplasm Metastasis 3Meningioma 3Melanoma 3Carcinoma, Non-Small-Cell Lung 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Ovarian Neoplasms 2Neuroectodermal Tumors, Primitive 2Lymphoma 2Liver Neoplasms 2Ependymoma 2Breast Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Teratoma, Testicular 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1

Interventions

Cyclophosphamide 2sargramostim 1poly ICLC 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lorvotuzumab mertansine 1ixabepilone 1fludarabine 1cixutumumab 1aldesleukin 1Zoledronic Acid 1Trabectedin 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Interleukin-2 1Immunotherapy, Adoptive 1Immunotherapy 1Drug Therapy 1Decitabine 1CLR1404 1Biological Therapy 1Ado-Trastuzumab Emtansine 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × aldesleukin × CNS × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡